Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18M | Gross Profit |
-1.18M | 0.00 | -836.00K | -1.47M | -736.00K | 107.00K | EBIT |
-111.58M | -142.47M | -170.28M | -127.44M | -83.56M | -43.66M | EBITDA |
-109.78M | -132.25M | -158.40M | -121.95M | -83.47M | -43.46M | Net Income Common Stockholders |
-109.37M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
127.76M | 127.76M | 182.74M | 282.91M | 363.67M | 434.22M | Total Assets |
147.78M | 147.78M | 242.55M | 306.49M | 380.18M | 436.05M | Total Debt |
9.90M | 435.00K | 17.20M | 10.43M | 742.00K | 0.00 | Net Debt |
-7.66M | -17.13M | -5.21M | -272.48M | -362.93M | -434.22M | Total Liabilities |
34.16M | 34.16M | 52.84M | 43.02M | 17.13M | 436.05M | Stockholders Equity |
113.62M | 113.62M | 189.71M | -325.47M | -201.99M | -118.52M |
Cash Flow | Free Cash Flow | ||||
-85.78M | -122.36M | -131.64M | -90.65M | -73.02M | -38.32M | Operating Cash Flow |
-80.02M | -121.91M | -130.36M | -89.22M | -68.10M | -38.29M | Investing Cash Flow |
-264.97M | 86.26M | 44.66M | -235.42M | -4.92M | 610.00K | Financing Cash Flow |
1.47M | 30.82M | 59.29M | 9.86M | 2.47M | 462.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | $272.31M | ― | -270.01% | ― | -65.96% | 40.80% | |
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
41 Neutral | $17.33M | ― | -66.15% | ― | 43.03% | 81.75% | |
41 Neutral | $28.33M | ― | -853.05% | ― | ― | 34.97% | |
39 Underperform | $24.78M | ― | -102.99% | ― | ― | 30.37% | |
39 Underperform | $24.81M | ― | -70.06% | ― | 146.47% | 57.85% | |
32 Underperform | $21.29M | ― | -1738.36% | ― | -43.55% | -293.22% |
On February 28, 2025, ALX Oncology Holdings Inc. announced a 30% reduction in its workforce as part of a strategy to prioritize its pipeline, focus on clinical development, and preserve cash. This reduction, expected to be completed by May 2025, will incur estimated expenses of $2.2 million primarily related to research and preclinical development. Additionally, the company’s President and Chief Scientific Officer, Jaume Pons, Ph.D., will depart in April 2025 as a result of this workforce reduction. Dr. Pons will receive severance benefits and will enter a consulting agreement to assist with the transition.